214 related articles for article (PubMed ID: 11116211)
1. Characterization of glucagon-like peptide-1 receptor-binding determinants.
Xiao Q; Jeng W; Wheeler MB
J Mol Endocrinol; 2000 Dec; 25(3):321-35. PubMed ID: 11116211
[TBL] [Abstract][Full Text] [Related]
2. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
[TBL] [Abstract][Full Text] [Related]
3. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
[TBL] [Abstract][Full Text] [Related]
4. The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system.
Takhar S; Gyomorey S; Su RC; Mathi SK; Li X; Wheeler MB
Endocrinology; 1996 May; 137(5):2175-8. PubMed ID: 8612565
[TBL] [Abstract][Full Text] [Related]
5. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain.
Tibaduiza EC; Chen C; Beinborn M
J Biol Chem; 2001 Oct; 276(41):37787-93. PubMed ID: 11498540
[TBL] [Abstract][Full Text] [Related]
6. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
Graziano MP; Hey PJ; Strader CD
Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of human incretin receptor missense variants.
Fortin JP; Schroeder JC; Zhu Y; Beinborn M; Kopin AS
J Pharmacol Exp Ther; 2010 Jan; 332(1):274-80. PubMed ID: 19841474
[TBL] [Abstract][Full Text] [Related]
8. Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling.
Unson CG; Wu CR; Jiang Y; Yoo B; Cheung C; Sakmar TP; Merrifield RB
Biochemistry; 2002 Oct; 41(39):11795-803. PubMed ID: 12269822
[TBL] [Abstract][Full Text] [Related]
9. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
Al-Sabah S; Donnelly D
Br J Pharmacol; 2003 Sep; 140(2):339-46. PubMed ID: 12970080
[TBL] [Abstract][Full Text] [Related]
10. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
[TBL] [Abstract][Full Text] [Related]
11. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
12. Isolation and structure-function studies of a glucagon-like peptide 1 receptor from goldfish Carassius auratus: identification of three charged residues in extracellular domains critical for receptor function.
Yeung CM; Mojsov S; Mok PY; Chow BK
Endocrinology; 2002 Dec; 143(12):4646-54. PubMed ID: 12446592
[TBL] [Abstract][Full Text] [Related]
13. Transmembrane α-helix 2 and 7 are important for small molecule-mediated activation of the GLP-1 receptor.
Rye Underwood C; Møller Knudsen S; Schjellerup Wulff B; Bräuner-Osborne H; Lau J; Knudsen LB; Peters GH; Reedtz-Runge S
Pharmacology; 2011; 88(5-6):340-8. PubMed ID: 22134089
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.
Volz A; Göke R; Lankat-Buttgereit B; Fehmann HC; Bode HP; Göke B
FEBS Lett; 1995 Oct; 373(1):23-9. PubMed ID: 7589426
[TBL] [Abstract][Full Text] [Related]
15. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
[TBL] [Abstract][Full Text] [Related]
16. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
[TBL] [Abstract][Full Text] [Related]
17. Development of a cysteine-deprived and C-terminally truncated GLP-1 receptor.
Underwood CR; Knudsen LB; Garibay PW; Peters GH; Reedtz-Runge S
Peptides; 2013 Nov; 49():100-8. PubMed ID: 24045233
[TBL] [Abstract][Full Text] [Related]
18. Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.
Runge S; Wulff BS; Madsen K; Bräuner-Osborne H; Knudsen LB
Br J Pharmacol; 2003 Mar; 138(5):787-94. PubMed ID: 12642379
[TBL] [Abstract][Full Text] [Related]
19. Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation.
Moon MJ; Kim HY; Park S; Kim DK; Cho EB; Park CR; You DJ; Hwang JI; Kim K; Choe H; Seong JY
J Biol Chem; 2012 Feb; 287(6):3873-84. PubMed ID: 22105074
[TBL] [Abstract][Full Text] [Related]
20. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
